Ftse Mib
33.973,54
1,02%
DAX
18.175,21
1,01%
S&P 500
5.157,02
0,57%
NASDAQ
16.283,36
0,79%
Bitcoin
63.576,37
-0,66%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Nurix Therapeutics Inc (NRIX) Nurix Therapeutics Inc (NRIX) Notizie

Nurix Therapeutics Inc

NRIX
13,22
0,44 (3,44%)
Ultimo aggiornamento: 17:47:01
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/4/202400:21GLOBENurix Therapeutics Announces Closing of Public Offering and..
12/4/202405:38GLOBENurix Therapeutics Announces Pricing of Upsized $175.0..
11/4/202422:00GLOBENurix Therapeutics Announces Proposed Public Offering
10/4/202413:00GLOBENurix Therapeutics Reports First Quarter Fiscal 2024..
09/4/202419:15GLOBENurix Therapeutics Reports First Clinical Evidence of CNS..
09/4/202413:00GLOBENurix Therapeutics Announces Extension of Strategic..
03/4/202413:00GLOBENurix Therapeutics to Participate in Upcoming Investor..
02/4/202413:00GLOBENurix Therapeutics Announces Extension of Strategic..
25/3/202412:00GLOBENurix Therapeutics is Part of a Team of International..
20/3/202414:40GLOBENurix Presents the Discovery and Chemical Structure of..
11/3/202412:02EDGAR2Form 8-K - Current report
11/3/202412:00GLOBENurix Therapeutics Announces U.S. FDA Lifts Partial Clinical..
06/3/202422:00GLOBENurix Therapeutics to Participate in Upcoming Investor..
05/3/202422:30GLOBENurix Therapeutics Announces Presentations at the American..
17/2/202401:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
15/2/202422:51EDGAR2Form S-8 - Securities to be offered to employees in employee..
15/2/202422:01EDGAR2Form 8-K - Current report
15/2/202422:00GLOBENurix Therapeutics Reports Fourth Quarter and Fiscal Year..
15/2/202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202414:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202422:01GLOBENurix Therapeutics Announces Publication in the Journal..
31/1/202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/1/202422:48DJNNurix Therapeutics Gets FDA Fast-Track Designation for..
16/1/202422:01GLOBENurix Therapeutics Receives U.S. FDA Fast Track Designation..
08/1/202413:03EDGAR2Form 8-K - Current report
08/1/202413:00GLOBENurix Therapeutics Outlines 2024 Strategic Priorities with..
02/1/202422:01GLOBENurix Therapeutics to Present at 42nd Annual J.P. Morgan..
21/12/202323:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202322:19EDGAR2Form 144 - Report of proposed sale of securities
13/12/202322:32GLOBEJudith A. Reinsdorf and Katherine M. Sandstrom Named to Toll..
11/12/202318:03EDGAR2Form 8-K - Current report
11/12/202318:00GLOBENurix Therapeutics Presents Positive Clinical Data from Its..
04/12/202322:01GLOBENurix Therapeutics Announces Webcast To Review Data from Its..
13/11/202313:01EDGAR2Form 8-K - Current report
07/11/202322:01GLOBENurix Therapeutics to Participate in Upcoming Investor..
02/11/202314:00GLOBENurix Therapeutics Announces Presentations at the 65th..
01/11/202322:16DJNNurix Therapeutics Says FDA Places Partial Clinical Hold on..
01/11/202321:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202321:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202321:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202321:02EDGAR2Form 8-K - Current report
01/11/202321:01GLOBENurix Therapeutics Announces Partial Clinical Hold For..
12/10/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apertura: 12,81 Min: 12,77 Max: 13,51
Chiusura: 12,78

La tua Cronologia

NASDAQ
NRIX
Nurix Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network